News

Public · Published

Rockwell Medical to Acquire Vantive Hemodialysis Business for $125 Million Base Price

Rockwell Medical signed an Equity and Asset Purchase Agreement to buy Vantive's in-center hemodialysis business across 35 jurisdictions, including the United States, for a $125 million base price. The price is adjustable and the deal is subject to regulatory approvals and closing conditions.

Published:

Updated:

What happened

Rockwell Medical signed an Equity and Asset Purchase Agreement to buy Vantive's in-center hemodialysis business across 35 jurisdictions, including the United States, for a $125 million base price. The price is adjustable and the deal is subject to regulatory approvals and closing conditions.

Confirmed

Global impact / market context

The deal expands Rockwell's hemodialysis products and services business, a core part of its revenue. Because most of the price is paid with $100 million of borrowed money from the seller and a $25 million convertible note, which means debt that can later turn into shares, Rockwell adds debt and possible share dilution.

Analyst inference

The structure shifts much of the financing risk to Vantive, which provides the term loans, meaning scheduled loans. Up to $45 million of extra earnout payments depend on future results, so final cost could rise. Investors will weigh added debt and share dilution against growth.

Analyst inference

What to watch

  1. The transaction needs regulatory approvals and other closing conditions, so completion is not assured and timing is unclear. Confirmed
  2. Rockwell plans to fund the $125 million base price mainly with $100 million of seller-provided term loans and a $25 million convertible note, which means debt and possible new shares. Proposed
  3. Watch whether up to $45 million in earnout payments becomes due, since that would raise the total cost and could pressure cash available and profit per sale. Analyst inference

Evidence

  • Original source link unavailable